miércoles, 19 de febrero de 2020

Can new trial data pull the microbiome industry out of the shadows?

Can new trial data pull the microbiome industry out of the shadows?

Daily Recap

STAT Plus: Microbiome-based drug makers are hoping new late-stage data will pull the field out of the shadows

By KATE SHERIDAN


ALEX HOGAN/STAT
The data will thrust the microbiome industry into the spotlight, its first since a high-profile clinical failure in 2016 threw a shadow over the field.

No hay comentarios: